Nitrosourea or mitomycin C within  weeks
Received -bis(-chloroethyl)-nitrosourea (BCNU or Carmustine) within  weeks prior to anticipated first dose of G-CSF.
Patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n*  weeks from the completion of radiation\r\n*  weeks from a nitrosourea chemotherapy\r\n*  weeks from a non-nitrosourea chemotherapy\r\n*  weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n*  weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.)
Cytotoxic chemotherapy, surgery, immunotherapy, radiotherapy or other targeted therapies within  weeks ( weeks in cases of ramucirumab, mitomycin C, nitrosourea, lomustine;  weeks in case of biopsy) prior to randomization (Adjuvant radiotherapy given to local area for non-curative symptom relief is allowed until  weeks before randomization.).
Minimum interval since last drug therapy:\r\n*  weeks since last non-cytotoxic therapy\r\n*  weeks must have elapsed since the completion of non-nitrosourea-containing chemotherapy regimen\r\n*  weeks since the completion of a nitrosourea-containing therapy regimen
Radiation therapy, chemotherapy, and other investigational agents within  weeks ( weeks for nitrosourea or mitomycin C) prior to starting fenretinide + safingol; patients must have recovered from toxicities of prior therapy
Mitomycin C or a nitrosourea:  weeks
Nitrosourea or mitomycin C within  weeks of the first dose
<  days from prior temozolomide, <  weeks from nitrosourea, <  weeks from other chemotherapy or investigational agents prior to start of treatment within study.
Minimum interval since last drug therapy:\r\n*  weeks since last non-cytotoxic therapy\r\n*  weeks must have elapsed since the completion of a non-nitrosourea-containing chemotherapy regimen\r\n*  weeks since the completion of a nitrosourea-containing chemotherapy regimen
Chemotherapy within  weeks of starting study drug ( weeks if prior nitrosourea)
Wash-out requirements (standard or investigational):\r\n* At least  weeks since the completion of a nitrosourea-containing chemotherapy regimen; and\r\n* At least  days must have passed since the completion of Temodar and/or  weeks for any other non-nitrosourea-containing cytotoxic chemotherapy regimen; if a participants most recent treatment was with a targeted agent only, and s/he has recovered from any toxicity of this targeted agent, then a waiting period of only  weeks is needed from the last dose and the start of CAR T cell infusion with the exception of bevacizumab where a wash out period of at least  weeks is required before starting CAR T cell therapy
Concurrent or recent chemotherapy, radiotherapy, or general anesthesia/major surgery within  weeks. Patients must have recovered from all known or expected toxicities from previous treatment and passed a treatment-free \washout\ period of  weeks before starting this program ( weeks for persons receiving nitrosourea or mitomycin).
Concurrent or recent chemotherapy (within  weeks), XRT within  weeks, may have had immunotherapy in the past (off within  weeks), or general anesthesia/major surgery (within  weeks). Patients must have recovered from all known or expected toxicities from previous treatment and passed a treatment-free \washout\ period of  weeks before starting this program ( weeks for persons receiving nitrosourea or mitomycin).
Patients must not be receiving concurrent anti-tumor treatment and must have recovered from toxicity of prior treatment. Minimum interval required: ) >  weeks following nitrosourea chemotherapy; ) >  weeks after recovering from any non-nitrosourea drug or systemic investigational agent; ) >  weeks after receiving any non-cytotoxic anti-tumor drug; ) >  weeks after receiving radiation therapy (>  weeks following upfront concurrent chemoradiation); ) >  weeks following Optune device use.
Patients may not have received chemotherapy or bevacizumab =<  weeks (except for nitrosourea [ weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [ week]) prior to starting the study drug unless patients have recovered from side effects of such therapy
Treatment with systemic antineoplastic therapy (including unconjugated therapeutic antibodies and toxin immunoconjugates) or any investigational therapy within  weeks (<  weeks for nitrosourea or mitomycin-C, antibodies except for trastuzumab) or within -half lives of the investigational therapy prior to starting study treatment, whichever is longer
 weeks from prior chemotherapy (  weeks for mitomycin C and nitrosourea) , immunotherapy, investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicities
Patients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosourea, mitomycin-C, targeted therapy and radiation) =<  weeks prior to starting study drug
Patients who have received the last administration of nitrosourea or mitomycin-C =<  weeks prior to starting study drug
Wash-out requirements (standard or investigational):\r\n* At least  weeks since the completion of a nitrosourea-containing chemotherapy regimen\r\n* At least  days since the completion of Temodar and/or  weeks for any other non-nitrosourea-containing cytotoxic chemotherapy regimen; if a patients most recent treatment was with a targeted agent only, and s/he has recovered from any toxicity of this targeted agent, then a waiting period of only  weeks is needed from the last dose and the start of study treatment, with the exception of bevacizumab where a wash out period of at least  weeks is required before starting study treatment
Any number of prior therapies is permitted; from the start of study treatment, the following time periods must have elapsed:  weeks from nitrosourea-containing chemotherapy,  weeks from non-nitrosourea-containing cytotoxic chemotherapy (except  days from last daily dose of temozolomide taken in a  of  day regimen), and  weeks from last dose of a targeted agent (except  weeks for bevacizumab); there is no time period requirement for prior radiation therapy
Have received radiotherapy, chemotherapy, biological therapy or investigational treatment less than four weeks (six weeks for nitrosourea or mitomycin C) prior to first dose of study medication or have not recovered from all acute toxicities from prior treatments.
Minimum interval since last investigational agent and/or prior cytotoxic drug therapy (patient must have also recovered from the toxic effects of any prior therapy):\r\n*  weeks since last non-cytotoxic therapy\r\n*  weeks must have elapsed since the completion of a non-nitrosourea-containing chemotherapy regimen\r\n*  weeks since the completion of a nitrosourea-containing chemotherapy regimen
Patients who have received chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug; all side effects from prior therapy must recover to grade  or less prior to starting on trial
Use of systemic anti-cancer therapy ?  weeks, or six weeks if the systemic therapy contains a nitrosourea or mitomycin C.
Nitrosourea cytotoxic drug ?  weeks
Non-nitrosourea cytotoxic drug or any systemic investigational agent with exception of methotrexate ?  weeks
Part  patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n*  weeks from the completion of radiation \r\n*  weeks from a nitrosourea chemotherapy or mitomycin C\r\n*  weeks from a non-nitrosourea chemotherapy\r\n*  weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n*  weeks from administration of a non-cytotoxic, FDA-approved agent, except bevacizumab/ vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g., erlotinib, hydroxychloroquine, etc.)\r\n*  weeks from bevacizumab/VEGFR inhibitors
Patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n*  weeks from the completion of radiation \r\n*  weeks from a nitrosourea chemotherapy\r\n*  weeks from a non-nitrosourea chemotherapy\r\n*  weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n*  weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.)
Patients must not have received nitrosourea or mitomycin C within  days prior to sub-study registration
Patients who have received oral or IV chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to study enrollment; steroids used for anti-cancer properties must be tapered to  mg or less of prednisone (or equivalent) for at least  weeks prior to initiating therapy
Patient has not recovered from any toxicity of prior therapies; an interval of \r\n* At least  weeks must have elapsed since taking a nitrosourea-containing chemotherapy regimen\r\n* At least  weeks since completing a non-nitrosourea-containing cytotoxic chemotherapy regimen (except temozolomide: only an interval of  days is required from the last does administered when patient has been recently treated with the standard temozolomide regimen of daily for  days, repeated every  days)\r\n* At least  weeks from taking the last dose of targeted agent\r\n* At least  weeks from the last dose of bevacizumab
Patients who have received chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
Completed nitrosourea treatment at least  weeks before administration of any study drug
Completed nitrosourea treatment at least  weeks before administration of any study drug
Completed nitrosourea treatment at least  weeks before administration of any study drug
Patient has received chemotherapy, targeted anticancer therapy, pelvic and/or para-aortic radiotherapy or has had major surgery =<  weeks ( weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy
Platelets ?,/?L (?,/?L, if within  weeks of prior nitrosourea treatment).
At the time of enrollment, patients must be ?  weeks since all of the following treatments (and recovered from the toxicity of prior treatment to <= Grade , exclusive of alopecia): major surgery; radiotherapy; chemotherapy (note: must be ?  weeks since therapy if treated with a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab); immunotherapy; Biotherapy/targeted therapies.
Patient has received chemotherapy or targeted anticancer therapy, monoclonal antibodies =<  weeks or  half-lives, whichever is shorter, or  weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered side the side effects of such therapy
Patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g.  weeks for nitrosourea, mitomycin-C) prior to starting study treatment
Prior nitrosourea or mitomycin C =<  weeks prior to registration
Patients who have received chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade  before starting the trial
Patients who have received oral or IV chemotherapy, targeted anticancer therapy or radiation therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to study enrollment
Patients who have received chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade  before starting the trial
Patients must be ?  weeks since major surgery, chemotherapy (-weeks if they were treated with a nitrosourea or mitomycin) or biotherapy/target therapies and ?  weeks since radiotherapy.
Patients who have received chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade  before starting the trial
Patients who have received chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C, and  week for hormone therapy) prior to starting study drug or who have not recovered from side effects of such therapy
Other chemotherapy (e.g., mitomycin-C, nitrosourea) or immunotherapy (e.g., antibody, cytokine) within  weeks
Patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n*  weeks from the completion of radiation\r\n*  weeks from a nitrosourea chemotherapy\r\n*  weeks from a non-nitrosourea chemotherapy\r\n*  weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n*  weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.)\r\n*  weeks from prior antiangiogenesis therapy (approved or investigational) (e.g., bevacizumab, aflibercept, ramucirumab, cediranib, cabozantinib, etc.)
Participant who received a prior treatment intended for antitumor effect (medication, surgery, radiotherapy, etc.) within  weeks prior to the planned first day of study drug dosing (or participant who received mitomycin C or Nitrosourea within  weeks prior to the planned first day of study drug dosing).
Mitomycin-C or nitrosourea therapy for at least  days and biologic agents for at least  days.
Patient has received chemotherapy or anticancer therapy ?  weeks ( weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug.
Patients who have received prior systemic anti-cancer treatment, such as cyclical chemotherapy or biological therapy within a period of time that is shorter than the cycle length used for that treatment (e.g.  weeks for nitrosourea, mitomycin-C) prior to starting study treatment.
Systemic anticancer treatment (including biologic therapy/antibodies) within  weeks before first dose of study treatment ( weeks for nitrosourea, mitomycin, and monoclonal antibodies).
Prior treatment with a Smoothened inhibitor Systemic anticancer treatment within  weeks before first dose of study treatment ( weeks for nitrosourea, mitomycin, and monoclonal antibodies).
Chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug
Patients who have received the last administration of nitrosourea or mitomycin-C =<  weeks prior to starting study drug, or who have side effects (except alopecia, lymphopenia and hyperglycemia) that have not resolved to NCI CTCAE grade or less
Completion of radiation therapy >=  weeks prior to registration and prior chemotherapy >=  weeks prior to registration (>=  weeks from nitrosourea-containing regimens)
Patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n*  weeks from the completion of radiation \r\n*  weeks from a nitrosourea chemotherapy\r\n*  weeks from a non-nitrosourea chemotherapy\r\n*  weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n*  weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., Tarceva, hydroxychloroquine, bevacizumab, etc.)
An interval of at least  months from the completion of most recent radiation therapy; at least  weeks from a non-nitrosourea chemotherapy regimen and at least  weeks from a nitrosourea containing regimen
Patients who have received chemotherapy or targeted anticancer therapy =<  weeks ( weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy (except alopecia)
All patients must be off previous chemo- and/or radiotherapy for at least three () weeks prior to entrance into the study and have recovered from any toxic effects induced by such treatment(s). Patients who have received a nitrosourea type drug must have had no treatment within the last six weeks.
Patients who received anti-cancer therapy prior to the first dose of WNT within the following time frames:\r\n* Biological therapy with a prolonged half-life (e.g., monoclonal antibodies) within  weeks\r\n* Cytotoxic agents associated with delayed hematologic recovery (e.g., nitrosourea or mitomycin-C) within  weeks\r\n* Other systemic anti-cancer agents within  weeks\r\n* Radiotherapy within  weeks
Received the last administration of nitrosourea or mitomycin-C =<  days prior to study registration, or who have not recovered from the side effects of such therapy
No prior nitrosourea (e.g. lomustine, carmustine)
Patient has received chemotherapy, monoclonal antibodies or targeted anticancer therapy =<  weeks or  half-lives, whichever is shorter, or  weeks for nitrosourea or mitomycin-C prior to starting the study drug, or the patient has not recovered from the side effects of such therapy
Patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n*  weeks from the completion of radiation \r\n*  weeks from a nitrosourea chemotherapy or mitomycin C\r\n*  weeks from a non-nitrosourea chemotherapy\r\n*  weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n*  weeks from administration of a non-cytotoxic, FDA-approved agent except bevacizumab/vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g., erlotinib, hydroxychloroquine, etc.)\r\n*  weeks from bevacizumab/VEGFR inhibitors
Patients who have received prior systemic anticancer therapy ?  weeks prior to study start ( weeks for nitrosourea, antibodies, or mitomycin-C)